ClinicalTrials.gg
RecruitingNCT05564598Updated Oct 28, 2026

CMV CTLs in Neonates With CMV Infection

A Phase 2 interventional study of CMV Cytotoxic T-Lymphocytes and Anti-viral Therapy in Congenital Cytomegaloviral (CMV) Disease, sponsored by New York Medical College. Recruiting at 4 sites in United States. Open to participants aged 0 Days to 21 Days. Per ClinicalTrials.gov, last updated 2026-10-28.

Primary conditionnone(registry's first term: Disease)No conditionIs this wrong?Disease describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by New York Medical College · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.
Updated Oct 28, 2026Eligibility revisedInterventions changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
0 Days to 21 Days
Sex
All
01

Study summary

Patients with moderate or severe CMV disease less than 21 days old who have a maternal donor who has a CMV response to the peptivators will be screened.

All patients will receive treatment with valganciclovir or ganciclovir. There is a safety run in with treatment with CMV CTLs in cohort 1 and if found to be safe, will proceed to cohort 2 for randomization to receive antiviral therapy with or without CMV CTLs. There is a cross-over design for patient assigned to SOC only if they have persistent disease.

Funding source: FDA OOPD

Read the detailed description

Given the vulnerability and poor outcomes of preterm neonates and neonates in general to viral infection, including the need for prolonged antiviral therapy for 6 or more months to achieve just modest improvements in sensorineural functions, CMV CTL therapy offers a promising alternative. CMV CTL treatment will build on the hosts innate immune capacity to create a more effective and permanent defense against collateral injury arising from CMV infections.

Patients who meet all inclusion/exclusion criteria with a maternal donor who meet all donor criteria will be enrolled onto study.

Cohort 1 is a safety run-in; the first 3 patients enrolled will be treated with anti-viral and CMV CTLs. The external DSMB will review the data from the first patient, and if there are no adverse events or dose-limiting toxicities observed, approve patient 2, and then 3, 28 days after the prior patients last CTL infusion. Assuming there are no adverse events in any of the first 3 patients, the study will proceed to Cohort 2.

Cohort 2 will be randomized 1:1 to either anti-viral treatment alone or anti-viral treatment plus CMV CTLs.

Patients who are randomized to receive CMV CTLs will get their first infusion on Day 0. If the patient fails to achieve a CR, they may receive one infusion every 2 weeks up to 5 maximum CMV CTL infusions as long as there are no DLTs or AEs observed

Patients who are assigned the SOC are only may be able to cross-over to to receive CMV CTLs if they have persistent disease at day 28.

02

Conditions studied

  • Congenital Cytomegaloviral (CMV) Disease

Browse trials for

03

In context

Lead sponsor

New York Medical College is the lead sponsor of 71 studies on the registry; 24 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
0 Days to 21 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: ≤ 21 days of life
  • Birth Weight: ≥ 2500 gms. . For babies with intrauterine growth retardation (IUGR) (small for gestational age [SGA]) > 1500 gms
  • Gestational age: ≥ 34 weeks of age
  • Diagnosis of CMV viremia, viruria, and/or infection:Either one or more:

Elevated CMV by RT-PCR in urine, saliva, CSF, or plasma; and/or Positive urine culture for CMV

- Moderate or Severe CMV Disease

Any one or more of the following attributable to congenital CMV infection:

  • Thrombocytopenia (≤ 50,000 mm3)
  • Multiple petechiae
  • Hepatomegaly
  • Splenomegaly
  • Intrauterine growth retardation
  • Increased transaminases
  • Increased
  • Microcephaly
  • Ventriculomegaly
  • Intracerebral calcifications
  • Periventricular echogenicity
  • Cortical or cerebral malformation
  • Chorioretinitis
  • Severe neonatal hearing loss
  • CMV DNA by PCR in CNS
  • Increased WBC for age in CNS

    • Minimal Organ Criteria Hematological: ≥ 750/mm3, HgB ≥ 8gm/dl, ≥ 20,000/kmm3 Renal: Serum creatinine ≤ 1.0 mg/dl Hepatic: /SGOT ≤3x upper normal limits
    • Donor Availability: Maternal donor available with a T-cell response CMV MACS® PepTivators. the donor is considered suitable if the percentage of IFN-gamma+ T cells is > 0.01% after stimulation with PepTivators.

Exclusion criteria

Exclusion Criteria -

  • Patient receiving (> 0.5 mg/kg prednisone equivalent) on the same day of CMV CTL infusion. Antenatal steroids for lung maturation will have been cleared prior to CMV diagnosis.
  • Concomitant enrollment in another experimental clinical trial investigating the treatment of neonatal CMV viremia and/or infection.
  • Any medical condition that could compromise participation in the study according to the investigator's assessment.
  • Known history of infection in the mother.
  • Patient's legally authorized representative unwilling or unable to comply with the protocol or unable to give .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (estimated)

Study arms

  • Experimental
    Cohort 1 Safety Run-in

    The first 3 patients enrolled will receive both anti-viral medication and CMV CTLs, and treatment will be staggered every 28 days from the last dose of CMV CTLs from the prior patient.

    Biological: CMV Cytotoxic T-Lymphocytes · Drug: Anti-viral Therapy

  • Experimental
    Cohort 2 Antiviral medication + CMV CTLs

    Patients will receive both anti-viral medication and CMV CTLs

    Biological: CMV Cytotoxic T-Lymphocytes · Drug: Anti-viral Therapy

  • Active comparator
    Cohort 2 Antiviral medication only

    Patients will only receive anti-viral therapy

    Drug: Anti-viral Therapy

  • Experimental
    Cross-Over

    Patients assigned to the SOC may be eligible to cross-over to the CVM CTL treatment if they are not responding to SOC treatment with continued elevated CMV levels.

    Biological: CMV Cytotoxic T-Lymphocytes · Drug: Anti-viral Therapy

Interventions

  • BiologicalCMV Cytotoxic T-Lymphocytes

    Patients will receive maternal CMV CTLs on day 0. Additional doses of CMV CTLs may be re-infused at a minimum of every two weeks for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg) only in patients not achieving a CR and no prior dose limiting toxicity of any prior dose.

    Also known as: CTLs

  • DrugAnti-viral Therapy

    All patients will receive anti-viral therapy with one of the following: 4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h Dose adjustments: * Reduce dose by 50% for ANC less than 500 cells/mm3 * Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3 * Treatment will continue for 6 months

    Also known as: valganciclovir, ganciclovir

06

What researchers measure

Primary outcomes

  1. To determine the safety of giving CMV CTLs combined with anti-viral therapy in neonates with CMV

    the incidence and severity of Grade I-IV acute GVHD within 8 weeks that is probably or directly related to CMV-CTL infusion after last CMV CTL infusion will be evaluated to determine the safety profile of CMV CTLs in neonates

    Time frame: 12 weeks

  2. To determine response rates to treatment with CMV CTLS and anti-viral medication

    response rates will be measured by monitoring CMV PCR levels. A complete response to CMV-CTLs will be those with undetectable viral load by qRT-PCR

    Time frame: 12 weeks

07

Study locations

4 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Oct 2027, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Oct 3, 2022
StartActual
Jul 1, 2023
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • New York Medical College · Vallhala, United States
Show 1 removed
  • New York Medical College · Valhalla, United States
Oct 28, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Birth Weight: ≥ 2500 gmsNow Birth Weight: ≥ 2500 gms. . For babies with intrauterine growth retardation (IUGR) (small for gestational age [SGA]) > 1500 gms
Oct 28, 2026
Interventions
Arms added: Cross-Over
Oct 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Children's Hospital Los Angeles · Los Angeles, United StatesContact n•••@chla.usc.edu→a•••@chla.usc.edu
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    1 site added, 1 site removed
    Show site
    • New York Medical College · Vallhala, United States
    Show 1 removed
    • New York Medical College · Valhalla, United States
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Birth Weight: ≥ 2500 gmsNow Birth Weight: ≥ 2500 gms. . For babies with intrauterine growth retardation (IUGR) (small for gestational age [SGA]) > 1500 gms
    Interventions Arms added: Cross-Over
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Children's Hospital Los Angeles · Los Angeles, United StatesContact n•••@chla.usc.edu→a•••@chla.usc.edu
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05564598
Lead sponsor
New York Medical College
Responsible party
Mitchell Cairo (Principal Investigator, New York Medical College) — Principal investigator
First posted
Oct 3, 2022
Start date
Jul 1, 2023
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Mitchell Cairo, MD
Contact
mitchell_cairo@nymc.edu
914-594-2150
Edo Schaefer, MD
Contact
eshaefe@nymc.edu
Mitchell Cairo, MD
principal investigator · New York Medical College

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion